Study highlights transformation of Hodgkin's into non-Hodgkin's lymphoma
According to Canadian researchers, those diagnosed with a traditionally rare subtype of Hodgkin's lymphoma need to be especially vigilant because of the subtype's "underappreciated" capacity to transform into an aggressive form of non-Hodgkin's lymphoma many years down the road.
A study out of the British Columbia Cancer Agency and published online, ahead of print, on 4 January 2010 in the Journal of Clinical Oncology, looked at patients diagnosed with nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) over a 40 year period and determined that 14% of those patients "experienced transformation to aggressive lymphoma" (median time to transformation, 8.1 years), namely secondary diffuse large B-cell lymphoma (DLBCL). The study urged long-term follow-up in order to better determine the risk factor associated with this transformation.
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is one of five subtypes of hodgkin's lymphoma, representing about 5% of all Hodgkin's diagnoses.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
